Clinical Trial Update: 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Everolimus to standard regimen in de novo kidney transplant patients; the study completed with results posted in May 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Kidney Transplantation, Renal Transplantation | Phase 3 | Status: COMPLETED | Results posted: 2017-05-01